Variation of the potential carbon mineralization (C–CO₂) at T₁₂₀ in the water samples incubations. حسب Daniel Cuevas-Lara (12188972)

الموضوعات:

DOC consumption at T₁₂₀ of the water samples incubations. حسب Daniel Cuevas-Lara (12188972)

الموضوعات:

Physical and land–cover features of the sampling sites of the Usumacinta River. حسب Daniel Cuevas-Lara (12188972)

الموضوعات:

Sampling sites (Lacantún, LCN; Balancán, BLN; Centla, CNT) at the Usumacinta River basin, southern Mexico. حسب Daniel Cuevas-Lara (12188972)

الموضوعات:

PCA of the dissolved nutrients in the Usumacinta River water samples at T0. حسب Daniel Cuevas-Lara (12188972)

الموضوعات:

Stepwise regression models for the C–CO₂ rates at the initial (T₀) and final (T₁₂₀; delta values) conditions of incubations. حسب Daniel Cuevas-Lara (12188972)

الموضوعات:

PCA of the dissolved nutrients’ deltas at T₁₂₀ in the water samples incubations. حسب Daniel Cuevas-Lara (12188972)

الموضوعات:

Upper quartile of district towns evaluated by the SD-TOPSIS technique ‐ combination of A, B1, B2 and C1. حسب Roman Vavrek (13200141)

Lower quartile of district towns evaluated by the SD-TOPSIS technique ‐ combination of A, B1, B1 and C1. حسب Roman Vavrek (13200141)

Source data for Fig 4C. حسب Isabel Raposo (21615517)

Source data for Fig 1C. حسب Isabel Raposo (21615517)

Growth kinetics of YFV-17D/Asibi chimeras in C6/36 cells. حسب Anja vom Hemdt (19787189)

الموضوعات:

Effect of supplementation of oocyte maturation medium (OMM) with follicular fluid (FF) from small or large follicles on development of embryos to the blastocyst stage. حسب Verónica M. Negrón-Pérez (20691412)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Overview of the six original ACTIV-3/TICO trials. حسب Elizabeth S. Munroe (21568166)

"…However, there is concern that by neutralizing the SARS-CoV-2 virus, nMAbs may decrease the availability of antigens to the immune system, potentially impairing the endogenous polyclonal immune response and decreasing long-term immune protection.…"

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)